Curaleaf (OTCMKTS:CURLF) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Curaleaf (OTCMKTS:CURLF) released its quarterly earnings results on Thursday. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.03, Zacks reports. Curaleaf had a negative return on equity of 15.57% and a negative net margin of 19.50%.

Curaleaf Stock Down 1.9%

Shares of Curaleaf stock traded down $0.05 during trading on Thursday, reaching $2.43. The company had a trading volume of 7,223,622 shares, compared to its average volume of 750,451. The company has a market cap of $1.65 billion, a price-to-earnings ratio of -7.60 and a beta of 0.74. The firm’s fifty day moving average is $2.53 and its 200-day moving average is $2.71. The company has a debt-to-equity ratio of 0.96, a quick ratio of 0.71 and a current ratio of 1.47. Curaleaf has a fifty-two week low of $0.68 and a fifty-two week high of $5.05.

Analysts Set New Price Targets

A number of equities analysts have commented on CURLF shares. Alliance Global Partners reiterated a “buy” rating on shares of Curaleaf in a report on Monday, December 22nd. ATB Cormark Capital Markets raised Curaleaf to an “outperform” rating in a research report on Tuesday, December 2nd. Finally, Zacks Research raised Curaleaf from a “strong sell” rating to a “hold” rating in a report on Thursday, January 1st. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and one has assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy”.

Curaleaf Company Profile

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.